Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

SH2B3 inactivation through CN-LOH 12q is uniquely associated with B-cell precursor ALL with iAMP21 or other chromosome 21 gain.

Sinclair PB, Ryan S, Bashton M, Hollern S, Hanna R, Case M, Schwalbe EC, Schwab CJ, Cranston RE, Young BD, Irving JAE, Vora AJ, Moorman AV, Harrison CJ.

Leukemia. 2019 Feb 28. doi: 10.1038/s41375-019-0412-1. [Epub ahead of print]

PMID:
30816328
2.

Dynamic clonal progression in xenografts of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21.

Sinclair PB, Blair HH, Ryan SL, Buechler L, Cheng J, Clayton J, Hanna R, Hollern S, Hawking Z, Bashton M, Schwab CJ, Jones L, Russell LJ, Marr H, Carey P, Halsey C, Heidenreich O, Moorman AV, Harrison CJ.

Haematologica. 2018 Apr;103(4):634-644. doi: 10.3324/haematol.2017.172304. Epub 2018 Feb 15.

3.

Analysis of a breakpoint cluster reveals insight into the mechanism of intrachromosomal amplification in a lymphoid malignancy.

Sinclair PB, Parker H, An Q, Rand V, Ensor H, Harrison CJ, Strefford JC.

Hum Mol Genet. 2011 Jul 1;20(13):2591-602. doi: 10.1093/hmg/ddr159. Epub 2011 Apr 12.

PMID:
21487021
4.

Insights into interphase large-scale chromatin structure from analysis of engineered chromosome regions.

Belmont AS, Hu Y, Sinclair PB, Wu W, Bian Q, Kireev I.

Cold Spring Harb Symp Quant Biol. 2010;75:453-60. doi: 10.1101/sqb.2010.75.050. Epub 2011 Apr 5.

5.

The facultative heterochromatin of the inactive X chromosome has a distinctive condensed ultrastructure.

Rego A, Sinclair PB, Tao W, Kireev I, Belmont AS.

J Cell Sci. 2008 Apr 1;121(Pt 7):1119-27. doi: 10.1242/jcs.026104. Epub 2008 Mar 11.

6.

A fluorescence in situ hybridization map of 6q deletions in acute lymphocytic leukemia: identification and analysis of a candidate tumor suppressor gene.

Sinclair PB, Sorour A, Martineau M, Harrison CJ, Mitchell WA, O'Neill E, Foroni L.

Cancer Res. 2004 Jun 15;64(12):4089-98.

7.

Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia.

Sinclair PB, Nacheva EP, Leversha M, Telford N, Chang J, Reid A, Bench A, Champion K, Huntly B, Green AR.

Blood. 2000 Feb 1;95(3):738-43.

8.
9.

Supplemental Content

Loading ...
Support Center